AI Summary & Key Takeaways
AI InsightConclusion: Pre-NAC; NLR and TLR were not successful in predicting the pathological complete response in patients with LABC.
📌 3 Key Takeaways
Abstract
Objectives: Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is com-monly accepted as the gold standard to assess outcome after NAC in patients with locally ad-vanced breast cancer (LABC). The immune system plays a key role in the response to NAC of patients with LABC. Neutrophil-to-lymphocyte ratio (NLR) and thrombocyteto-lymphocyte ratio (TLR) are peripheral blood indicators of inflammatory response. Here, we investigate the relationship between pCR and NLR-TLR and other clinicopathological features before patients receive NAC. Methods: Forty-two female patients with LABC, who received NAC between 2013 and 2021 were evaluated retrospectively. NLR and TLR were calculated with the values of neutrophils, lymphocytes, and thrombocytes in complete blood count at the time of diagnosis. The cut off values of NLR and TLR were determined using receiver operating characteristic (ROC) curve analysis. Results: Median age was 54.5 years (31-82). pCR was achieved in 16 (31.8%) of patients. Pa-tients divided into 2 groups according to NLR cut-off and TLR cut-off values as NLR/TLR high and low groups. The cut-off values of NLR and TLR were 2.27 and 130.25, respectively. There was no significant difference in pCR between NLR (high/low) and TLR (high/ low) groups (p=0.13/0.38 and 0.13/0.13, respectively). The pCR rate was higher in patients with ER negative and HER2 positive subgroups (p = 0.002, and 0.040, respectively). Conclusion: Pre-NAC; NLR and TLR were not successful in predicting the pathological complete response in patients with LABC.